Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TESTOSTERONE CYPIONATE vs ANDROID-F
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Testosterone cypionate is a synthetic androgen that binds to and activates androgen receptors, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development. It also suppresses gonadotropin release via negative feedback.
Fingolimod is a sphingosine 1-phosphate receptor modulator that sequesters lymphocytes in lymph nodes, reducing central nervous system immune cell infiltration.
Male hypogonadism (primary or hypogonadotropic),Delayed puberty in males,Off-label: Female-to-male gender affirmation therapy, anemia of renal failure (historically)
Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
Intramuscular injection of 50-400 mg every 2-4 weeks, typically 200 mg every 2 weeks or 400 mg every 4 weeks.
Adults: 1 tablet (methyltestosterone 2.5 mg, ethinyl estradiol 0.025 mg) orally once daily, with food.
Approximately 8 days (terminal elimination half-life of testosterone cypionate after intramuscular injection; due to slow release from oil depot, effective half-life in muscle is ~8 days with a longer terminal phase up to 3 weeks)
2.5-3.5 hours (terminal half-life); oral administration may require multiple daily doses for stable levels.
Primarily hepatic via CYP3A4 and CYP2B6; metabolites include androsterone and etiocholanolone; excreted in urine.
Metabolized primarily by CYP4F2, with minor contributions from CYP2D6, CYP2E1, CYP3A4, and CYP1A2. Undergoes biotransformation to an inactive metabolite.
Renal (90% as glucuronide and sulfate conjugates), fecal (10%)
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); small amount biliary/fecal.
97-99% bound to sex hormone-binding globulin (SHBG) and albumin
97-99% bound to sex hormone-binding globulin (SHBG) and albumin.
Approximately 0.6-1.0 L/kg (reflects extensive distribution into tissues, including muscle and fat; total Vd ~4-9 L in adults)
0.5-0.8 L/kg; reflects distribution into muscle, liver, and reproductive tissues.
Intramuscular: 100% (administered as a depot injection in oil; undergoes first-pass metabolism if oral, but not relevant for IM route)
Oral: 3-6% (extensive first-pass metabolism); IM: 100%.
No specific dose adjustment recommended; however, monitor fluid retention and hypertension in patients with severe renal impairment (GFR <30 m L/min).
GFR 10-50 m L/min: reduce dose by 50%. GFR <10 m L/min: avoid use.
Child-Pugh A/B: No adjustment; Child-Pugh C: Contraindicated due to risk of hepatotoxicity.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: avoid use. Child-Pugh C: contraindicated.
Not recommended for use in pediatric patients for hypogonadism; for delayed puberty, IM testosterone cypionate 50 mg every 4 weeks initially, titrating upward as needed.
Not recommended for use in children due to risk of premature epiphyseal closure and virilization.
Start at lower end of dosing range (e.g., 50-100 mg every 2-4 weeks) due to increased risk of prostate enlargement and cardiovascular events; monitor serum testosterone levels and adjust accordingly.
Use with caution; consider lower starting dose due to increased risk of fluid retention, hypertension, and prostatic hypertrophy in males.
Prolonged use of high doses of testosterone has been associated with an increased risk of hepatocellular carcinoma.
Risk of bradyarrhythmia and atrioventricular block, requiring first-dose monitoring for 6 hours. Fatal infections, including opportunistic infections, have occurred. Macular edema has been reported.
Risk of polycythemia (monitor hematocrit), edema in patients with cardiac/renal/hepatic disease, accelerated growth in prepubertal males (monitor bone age), gynecomastia, sleep apnea exacerbation, prostate hyperplasia/carcinoma (monitor PSA), decreased spermatogenesis, elevated blood pressure, hyperlipidemia.
May cause bradycardia and AV block; monitor heart rate after first dose. Increased risk of infections, including herpes viruses and cryptococcal meningitis. Macular edema, especially in patients with diabetes or uveitis. Posterior reversible encephalopathy syndrome (PRES). Respiratory effects, including decreased FEV1 and DLCO. Hepatic injury; monitor liver enzymes.
Known or suspected prostate carcinoma, male breast carcinoma, pregnancy, hypersensitivity to testosterone cypionate, severe hepatic/renal/cardiac disease (relative), hypercalcemia (in patients with immobility).
Recent myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure, history of Mobitz type II 2nd or 3rd degree AV block, sick sinus syndrome unless pacemaker is present, or severe untreated sleep apnea.
No significant food interactions. Limit alcohol consumption as it may increase risk of liver damage. Grapefruit juice may interfere with testosterone metabolism; avoid excessive intake.
No significant food interactions reported. Avoid excessive alcohol consumption due to hepatotoxic effects.
Testosterone cypionate is contraindicated in pregnancy. Androgenic effects may cause virilization of female fetus if exposed during organogenesis (first trimester). Second and third trimester exposure can also cause virilization. No adequate studies exist; use only if clearly needed for maternal condition, though use in pregnancy is generally avoided.
ANDROID-F contains methyltestosterone, a synthetic androgen. Androgens are teratogenic in humans. In first trimester: masculinization of female fetus, including clitoromegaly, labial fusion, and urogenital sinus abnormalities. Second and third trimesters: continued virilization of female fetus; no increased risk of malformations in male fetuses. Contraindicated in pregnancy.
Testosterone is excreted into breast milk in low concentrations; M/P ratio not reported. Theoretical risk of androgenic effects in male infants (e.g., masculinization). Use with caution only if maternal benefit outweighs potential risk. Consider alternative therapies while breastfeeding.
Methyltestosterone is excreted in breast milk. No specific M/P ratio available. May cause virilization in female infants and precocious development in male infants. Breastfeeding is contraindicated during therapy.
No specific dose adjustment studies exist. Pharmacokinetic changes during pregnancy (increased clearance, volume of distribution) may reduce efficacy, but use of testosterone cypionate during pregnancy is contraindicated. If essential, dose may need titration to maintain desired androgen levels; however, risk outweighs benefit.
ANDROID-F is contraindicated in pregnancy; no dosing recommendations for use in pregnancy. No established dose adjustments exist as the drug should not be administered.
Testosterone cypionate is a long-acting injectable androgen. Monitor hematocrit and hemoglobin due to risk of polycythemia. Use with caution in patients with sleep apnea, benign prostatic hyperplasia, or cardiovascular disease. Check serum testosterone levels 1 week after injection to assess adequacy. For men with hypogonadism, avoid in those with untreated hyperprolactinemia or pituitary tumor.
Android-F is a brand of methyltestosterone, an androgen used primarily for male hypogonadism. Monitor liver function due to potential hepatotoxicity. Avoid in males with breast or prostate cancer. Use with caution in older patients due to increased risk of prostatic hypertrophy. May suppress clotting factors II, V, VII, and X.
Inject deeply into the muscle (gluteal or thigh) to reduce pain and risk of abscess.,Do not use if you have breast cancer, prostate cancer, or are pregnant.,Report swelling in ankles, difficulty breathing, or severe headache immediately.,Do not take with blood thinners like warfarin without consulting your doctor.,Expect possible mood changes, increased acne, or hair loss. Monitor for priapism.,Regular blood tests are required to check red blood cell count, liver function, and prostate health.
Take exactly as prescribed; do not increase dose or frequency.,Report any signs of liver problems (yellowing eyes/skin, dark urine, persistent nausea) immediately.,Women should report hoarseness, acne, or menstrual changes.,Men should report frequent or persistent erections, or breast swelling/tenderness.,May cause decreased sperm count in men; discuss family planning.,Avoid concurrent use with other medications without consulting doctor.
"Chlorpropamide, a sulfonylurea antidiabetic agent, stimulates pancreatic insulin secretion, while testosterone may enhance insulin sensitivity and reduce blood glucose levels. Concurrent use can lead to additive hypoglycemic effects, increasing the risk of hypoglycemia, particularly in patients with diabetes. This interaction is of clinical concern as it may necessitate dose adjustments of chlorpropamide to prevent hypoglycemic episodes."
"Flunisolide, a corticosteroid with mineralocorticoid activity, can potentiate the sodium- and water-retaining effects of testosterone, leading to an increased risk of edema, hypertension, and exacerbation of heart failure. This interaction is particularly significant in patients with pre-existing cardiovascular conditions, as the combined effects on fluid balance may require dose adjustments or closer monitoring."
"Fluorometholone, a corticosteroid with mineralocorticoid activity, may enhance sodium and water retention induced by testosterone, particularly in patients with pre-existing cardiac or renal conditions. This interaction can lead to increased fluid retention, exacerbation of hypertension, and potential precipitation of congestive heart failure. The risk is greater with high doses or prolonged use of either agent."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TESTOSTERONE CYPIONATE vs ANDROID-F, answered by our medical review team.
TESTOSTERONE CYPIONATE is a Androgen that works by Testosterone cypionate is a synthetic androgen that binds to and activates androgen receptors, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development. It also suppresses gonadotropin release via negative feedback.. ANDROID-F is a Androgen/Estrogen Combination that works by Fingolimod is a sphingosine 1-phosphate receptor modulator that sequesters lymphocytes in lymph nodes, reducing central nervous system immune cell infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TESTOSTERONE CYPIONATE and ANDROID-F depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TESTOSTERONE CYPIONATE is: Intramuscular injection of 50-400 mg every 2-4 weeks, typically 200 mg every 2 weeks or 400 mg every 4 weeks.. The standard adult dose of ANDROID-F is: Adults: 1 tablet (methyltestosterone 2.5 mg, ethinyl estradiol 0.025 mg) orally once daily, with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TESTOSTERONE CYPIONATE and ANDROID-F in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TESTOSTERONE CYPIONATE is classified as Category D/X. Testosterone cypionate is contraindicated in pregnancy. Androgenic effects may cause virilization of female fetus if exposed during organogenesis (first trimester). Second and thir. ANDROID-F is classified as Category C. ANDROID-F contains methyltestosterone, a synthetic androgen. Androgens are teratogenic in humans. In first trimester: masculinization of female fetus, including clitoromegaly, labi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.